Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

D Armenia; D Di Carlo; Andrea CALCAGNO; GIULIA VENDEMIATI; F Forbici; A Bertoli; G Berno; S Carta; F Continenza; V Fedele; R Bellagamba; S Cicalini; A Ammassari; R Libertone; M Zaccarelli; V Ghisetti; M Andreoni; F Ceccherini Silberstein; Stefano BONORA; Giovanni DI PERRI; A Antinori; C. F Perno; M. M. Santoro

doi:10.1093/jac/dkw512

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

D Armenia
, D Di Carlo
, Andrea CALCAGNO
, GIULIA VENDEMIATI
, F Forbici
, A Bertoli
, G Berno
, S Carta
, F Continenza
, V Fedele
, R Bellagamba
, S Cicalini
, A Ammassari
, R Libertone
, M Zaccarelli
, V Ghisetti
, M Andreoni
, F Ceccherini Silberstein
, Stefano BONORA
, Giovanni DI PERRI

A Antinori, C. F Perno, M. M. Santoro

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen, by considering pre-existent resistance (pRes).

Lingua originale	Inglese
pagine (da-a)	1-11
Numero di pagine	11
Rivista	Journal of Antimicrobial Chemotherapy
DOI	https://doi.org/10.1093/jac/dkw512
Stato di pubblicazione	Pubblicato - 2016

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Accesso al documento

10.1093/jac/dkw512

https://hdl.handle.net/11579/216822

Altri file e collegamenti

handle

Cita questo

Armenia, D., Di Carlo, D., CALCAGNO, A., VENDEMIATI, GIULIA., Forbici, F., Bertoli, A., Berno, G., Carta, S., Continenza, F., Fedele, V., Bellagamba, R., Cicalini, S., Ammassari, A., Libertone, R., Zaccarelli, M., Ghisetti, V., Andreoni, M., Ceccherini Silberstein, F., BONORA, S., ... Santoro, M. M. (2016). Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. Journal of Antimicrobial Chemotherapy, 1-11. https://doi.org/10.1093/jac/dkw512

@article{cce6f046ed2245ffb32ff40106fc42bc,

title = "Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen",

abstract = "To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen, by considering pre-existent resistance (pRes).",

author = "D Armenia and \{Di Carlo\}, D and Andrea CALCAGNO and GIULIA VENDEMIATI and F Forbici and A Bertoli and G Berno and S Carta and F Continenza and V Fedele and R Bellagamba and S Cicalini and A Ammassari and R Libertone and M Zaccarelli and V Ghisetti and M Andreoni and \{Ceccherini Silberstein\}, F and Stefano BONORA and \{DI PERRI\}, Giovanni and A Antinori and Perno, \{C. F\} and Santoro, \{M. M.\}",

year = "2016",

doi = "10.1093/jac/dkw512",

language = "English",

pages = "1--11",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

}

Armenia, D, Di Carlo, D, CALCAGNO, A, VENDEMIATI, GIULIA, Forbici, F, Bertoli, A, Berno, G, Carta, S, Continenza, F, Fedele, V, Bellagamba, R, Cicalini, S, Ammassari, A, Libertone, R, Zaccarelli, M, Ghisetti, V, Andreoni, M, Ceccherini Silberstein, F, BONORA, S, DI PERRI, G, Antinori, A, Perno, CF & Santoro, MM 2016, 'Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen', Journal of Antimicrobial Chemotherapy, pagg. 1-11. https://doi.org/10.1093/jac/dkw512

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. / Armenia, D; Di Carlo, D; CALCAGNO, Andrea et al.
In: Journal of Antimicrobial Chemotherapy, 2016, pag. 1-11.

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

TY - JOUR

T1 - Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

AU - Armenia, D

AU - Di Carlo, D

AU - CALCAGNO, Andrea

AU - VENDEMIATI, GIULIA

AU - Forbici, F

AU - Bertoli, A

AU - Berno, G

AU - Carta, S

AU - Continenza, F

AU - Fedele, V

AU - Bellagamba, R

AU - Cicalini, S

AU - Ammassari, A

AU - Libertone, R

AU - Zaccarelli, M

AU - Ghisetti, V

AU - Andreoni, M

AU - Ceccherini Silberstein, F

AU - BONORA, Stefano

AU - DI PERRI, Giovanni

AU - Antinori, A

AU - Perno, C. F

AU - Santoro, M. M.

PY - 2016

Y1 - 2016

N2 - To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen, by considering pre-existent resistance (pRes).

AB - To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen, by considering pre-existent resistance (pRes).

UR - https://iris.uniupo.it/handle/11579/216822

U2 - 10.1093/jac/dkw512

DO - 10.1093/jac/dkw512

M3 - Article

SN - 0305-7453

SP - 1

EP - 11

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

ER -

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo